Loading clinical trials...

Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

Phase II Study of Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

NCT00193167•SCRI Development Innovations, LLC

Summary

This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.

Detailed Description

Upon determination of eligibility, patients will be receive: * Topotecan

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•To be included in this study, you must meet the following criteria:
•Metastatic colorectal cancer
•One previous chemotherapy for metastatic disease
•Measurable or evaluable disease
•Able to perform activities of daily living with assistance
•Adequate bone marrow, liver, and kidney function
•All patients must give written informed consent prior to study entry.

Exclusion Criteria

•You cannot participate in this study if any of the following apply to you:
•Brain or meningeal involvement
•Serious active infection or underlying medical conditions
•Other active neoplasms are ineligible
•Pregnant or lactating

Locations (1)

Tennessee Oncology

Nashville, Tennessee, United States

Key Dates

Start Date

January 1, 2004

Primary Completion Date

April 1, 2006

Completion Date

April 1, 2006

Last Updated

May 3, 2011

Enrollment

Estimated participants

Conditions

Colon Cancer

Interventions

Topotecan

DRUG

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGNA

Resilience and Equity in Aging, Cancer, and Health (REACH)

NCT04674267

Gastric CancerColon Cancer+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 3, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Resilience and Equity in Aging, Cancer, and Health (REACH)

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Phase II Trial of Lung Chemoemobolization

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression